<ul>
<li>3 支高股息股票，現在收入，未來增長</li>
</ul>
<p>百時美施貴寶（NYSE:BMY - 免費報告）- Zacks Research 的投資分析師在 6 月 26 日星期三向客户和投資者發佈的研究報告中，提高了他們對百時美施貴寶股票 2024 年第四季度每股收益（EPS）的預估。Zacks Research 分析師 E. Bagri 現在預計這家生物製藥公司本季度每股收益為 1.70 美元，高於他們之前的預估 1.69 美元。百時美施貴寶當前全年收益的共識預估為每股 0.58 美元。Zacks Research 還預測了百時美施貴寶 2026 財年的每股收益為 6.25 美元。</p>
<p>獲取 <strong>百時美施貴寶</strong> 警報：</p>
<p>BMY 已成為許多其他報告的話題。StockNews.com 在一份報告中將百時美施貴寶的評級從 “強烈買入” 調降為 “買入”，巴克萊在 4 月 26 日星期五的一份報告中將百時美施貴寶的目標股價從 51.00 美元降至 43.00 美元，並設定了 “等權重” 評級。Societe Generale 在 3 月 11 日星期一的一份研究報告中，將百時美施貴寶的評級從 “買入” 調降為 “持有”。BMO Capital Markets 在 4 月 26 日星期五的一份研究報告中，將百時美施貴寶的目標股價從 55.00 美元降至 48.00 美元，併為該公司設定了 “市場表現” 評級。最後，富國銀行將百時美施貴寶的目標股價從 51.00 美元上調至 52.00 美元，並在 4 月 18 日星期四的一份研究報告中為該股設定了 “等權重” 評級。一位研究分析師對該股票進行了賣出評級，十五位分析師給出了持有評級，四位分析師給出了買入評級。根據 MarketBeat.com 的數據，該公司目前的共識評級為 “持有”，平均目標股價為 60.00 美元。</p>
<p><strong>閲讀我們關於百時美施貴寶的最新報告</strong></p>
<h2>百時美施貴寶價格表現</h2>
<p>NYSE BMY 股票週一開盤價為 41.53 美元。該公司市值為 841.9 億美元，市盈率為-13.40，PEG 比率為 14.21，β值為 0.43。百時美施貴寶過去十二個月的最低價為 39.63 美元，最高價為 65.38 美元。該公司的速動比率為 0.99，流動比率為 1.11，負債股本比率為 2.99。該公司的 50 天移動平均價為 42.97 美元，200 天移動平均價為 48.11 美元。</p>
<p>百時美施貴寶（NYSE:BMY - 獲取免費報告）上次發佈財報是在 4 月 25 日星期四。這家生物製藥公司報告本季度每股虧損 4.40 美元，超過了每股虧損 4.53 美元的共識預估 0.13 美元。百時美施貴寶的淨資產回報率為 8.83%，淨利潤率為-13.50%。該公司本季度的營收為 118.7 億美元，高於 114.5 億美元的共識預估。與去年同期相比，該季度公司的營收增長了 4.7%。</p>
<h2>機構投資者對百時美施貴寶的看法</h2>
<p>對該公司的持股情況最近發生了變化。Northwest Financial Advisors 在第四季度購入了百時美施貴寶股票，價值 27000 美元。ESL Trust Services LLC 在第一季度購入了百時美施貴寶股票，價值約 27000 美元。Accordant Advisory Group Inc 在第一季度購入了百時美施貴寶股票，價值約 31000 美元。Pacific Capital Wealth Advisors Inc.在第四季度購入了百時美施貴寶股票，價值約 34000 美元。最後，Turtle Creek Wealth Advisors LLC 在第四季度購入了百時美施貴寶股票，價值 40000 美元。目前，76.41% 的股份由對沖基金和其他機構投資者持有。</p>
<h2>百時美施貴寶宣佈股息</h2>
<p>該公司最近宣佈了季度股息，將於 8 月 1 日星期四支付。股東記錄日期為 7 月 5 日星期五，將支付 0.60 美元的股息。該股息的除息日期為 7 月 5 日星期五。這代表了每年 2.40 美元的股息和 5.78% 的收益率。百時美施貴寶的派息比率為-77.42%。</p>
<h2>百時美施貴寶公司簡介（獲取免費報告）</h2>
<p>百時美施貴寶公司在全球範圍內發現、開發、許可、製造、市場、分銷和銷售生物製藥產品。它提供用於血液病學、腫瘤學、心血管病學、免疫學、纖維化和神經科學疾病的產品。該公司的產品包括 Eliquis，用於降低非瓣膜性心房顫動患者的中風/全身栓塞風險，並用於 DVT/PE 的治療；Opdivo，用於各種抗癌適應症，包括膀胱癌、血液癌、CRC、頭頸癌、RCC、HCC、肺癌、黑色素瘤、MPM、胃癌和食道癌；Pomalyst/Imnovid，用於多發性骨髓瘤；Orencia，用於活動性類風濕關節炎和銀屑病性關節炎；以及 Sprycel，用於費城染色體陽性慢性髓細胞白血病的治療。</p>
<h2>特色文章</h2>
<ul>
<li>我們喜歡的五支股票，比百時美施貴寶更好</li>
<li>市值計算器：如何計算市值</li>
<li>Upwork 股票前景：儘管面臨 Gen-AI 挑戰，數字仍穩固</li>
<li>使用 MarketBeat 股息率計算器</li>
<li>瓦爾格林股票暴跌背後：投資者下一步該怎麼做</li>
<li>寶潔 NYSE: PG 在搖擺的指引後回落</li>
<li>MarketBeat 周評 - 6/24 - 6/28</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ"/></p>
<p><em>這則即時新聞警報是由敍事科技和來自 MarketBeat 的金融數據生成，旨在為讀者提供最快速和最準確的報道。在發佈之前，該故事已經經過 MarketBeat 編輯團隊的審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com。</em></p>
<p>→ 特朗普的逮捕是第一階段（來自 Porter &amp; Company）(廣告)</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NjAw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NjAw"/></p>
<h2>現在是否值得投資$1,000 美元購買百時美施貴寶？</h2>
<p>在考慮購買百時美施貴寶之前，您可能想聽聽這個消息。</p>
<p>MarketBeat 每天跟蹤華爾街評級最高、表現最佳的研究分析師以及他們推薦給客户的股票。MarketBeat 已經確定了五隻頂級分析師悄悄告訴他們的客户現在應該購買的股票...而百時美施貴寶並不在名單上。</p>
<p>雖然百時美施貴寶目前在分析師中被評為 “持有” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

百時美施貴寶

<p>摩根士丹利研究的投資分析師調高了百時美施貴寶 2024 年第四季度的每股收益預期。預計這家生物製藥公司該季度每股收益為 1.70 美元。公司全年盈利的共識預期為每股 0.58 美元。百時美施貴寶 2026 財年的盈利預計為每股 6.25 美元</p>

<ul>
<li>3 High-Yield Dividend Stocks for Income Now and Growth Later</li>
</ul>
<div class="lb-trans"><ul>
<li>3 支高股息股票，現在收入，未來增長</li>
</ul>
</div><p>Bristol-Myers Squibb (NYSE:BMY - Free Report) - Investment analysts at Zacks Research increased their Q4 2024 earnings per share (EPS) estimates for shares of Bristol-Myers Squibb in a research report issued to clients and investors on Wednesday, June 26th. Zacks Research analyst E. Bagri now expects that the biopharmaceutical company will earn $1.70 per share for the quarter, up from their prior estimate of $1.69. The consensus estimate for Bristol-Myers Squibb's current full-year earnings is $0.58 per share. Zacks Research also issued estimates for Bristol-Myers Squibb's FY2026 earnings at $6.25 EPS.</p>
<div class="lb-trans"><p>百時美施貴寶（NYSE:BMY - 免費報告）- Zacks Research 的投資分析師在 6 月 26 日星期三向客户和投資者發佈的研究報告中，提高了他們對百時美施貴寶股票 2024 年第四季度每股收益（EPS）的預估。Zacks Research 分析師 E. Bagri 現在預計這家生物製藥公司本季度每股收益為 1.70 美元，高於他們之前的預估 1.69 美元。百時美施貴寶當前全年收益的共識預估為每股 0.58 美元。Zacks Research 還預測了百時美施貴寶 2026 財年的每股收益為 6.25 美元。</p>
</div><p>Get <strong>Bristol-Myers Squibb</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>百時美施貴寶</strong> 警報：</p>
</div><p>BMY has been the topic of a number of other reports. StockNews.com downgraded Bristol-Myers Squibb from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a report on Thursday. Barclays dropped their target price on shares of Bristol-Myers Squibb from $51.00 to $43.00 and set an &#34;equal weight&#34; rating on the stock in a report on Friday, April 26th. Societe Generale downgraded Bristol-Myers Squibb from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research note on Monday, March 11th. BMO Capital Markets reduced their price objective on Bristol-Myers Squibb from $55.00 to $48.00 and set a &#34;market perform&#34; rating for the company in a research report on Friday, April 26th. Finally, Wells Fargo &amp; Company raised their target price on Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an &#34;equal weight&#34; rating in a research report on Thursday, April 18th. One research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of &#34;Hold&#34; and an average target price of $60.00.</p>
<ul>
<li>Bounce Alert: 3 Large Caps With RSIs Too Good To Ignore</li>
</ul>
<div class="lb-trans"><p>BMY 已成為許多其他報告的話題。StockNews.com 在一份報告中將百時美施貴寶的評級從 “強烈買入” 調降為 “買入”，巴克萊在 4 月 26 日星期五的一份報告中將百時美施貴寶的目標股價從 51.00 美元降至 43.00 美元，並設定了 “等權重” 評級。Societe Generale 在 3 月 11 日星期一的一份研究報告中，將百時美施貴寶的評級從 “買入” 調降為 “持有”。BMO Capital Markets 在 4 月 26 日星期五的一份研究報告中，將百時美施貴寶的目標股價從 55.00 美元降至 48.00 美元，併為該公司設定了 “市場表現” 評級。最後，富國銀行將百時美施貴寶的目標股價從 51.00 美元上調至 52.00 美元，並在 4 月 18 日星期四的一份研究報告中為該股設定了 “等權重” 評級。一位研究分析師對該股票進行了賣出評級，十五位分析師給出了持有評級，四位分析師給出了買入評級。根據 MarketBeat.com 的數據，該公司目前的共識評級為 “持有”，平均目標股價為 60.00 美元。</p>
</div><p><strong>Read Our Latest Report on Bristol-Myers Squibb</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於百時美施貴寶的最新報告</strong></p>
</div><h2>Bristol-Myers Squibb Price Performance</h2>
<div class="lb-trans"><h2>百時美施貴寶價格表現</h2>
</div><p>Shares of NYSE BMY opened at $41.53 on Monday. The firm has a market cap of $84.19 billion, a P/E ratio of -13.40, a PEG ratio of 14.21 and a beta of 0.43. Bristol-Myers Squibb has a twelve month low of $39.63 and a twelve month high of $65.38. The company has a quick ratio of 0.99, a current ratio of 1.11 and a debt-to-equity ratio of 2.99. The company has a 50 day moving average of $42.97 and a 200 day moving average of $48.11.</p>
<ul>
<li>Geron Stock Doubles After Imetelstat Receives FDA Panel Approval</li>
</ul>
<div class="lb-trans"><p>NYSE BMY 股票週一開盤價為 41.53 美元。該公司市值為 841.9 億美元，市盈率為-13.40，PEG 比率為 14.21，β值為 0.43。百時美施貴寶過去十二個月的最低價為 39.63 美元，最高價為 65.38 美元。該公司的速動比率為 0.99，流動比率為 1.11，負債股本比率為 2.99。該公司的 50 天移動平均價為 42.97 美元，200 天移動平均價為 48.11 美元。</p>
</div><p>Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last released its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) EPS for the quarter, topping the consensus estimate of ($4.53) by $0.13. Bristol-Myers Squibb had a positive return on equity of 8.83% and a negative net margin of 13.50%. The business had revenue of $11.87 billion for the quarter, compared to the consensus estimate of $11.45 billion. During the same period in the previous year, the company posted $2.05 earnings per share. The company's revenue for the quarter was up 4.7% compared to the same quarter last year.</p>
<div class="lb-trans"><p>百時美施貴寶（NYSE:BMY - 獲取免費報告）上次發佈財報是在 4 月 25 日星期四。這家生物製藥公司報告本季度每股虧損 4.40 美元，超過了每股虧損 4.53 美元的共識預估 0.13 美元。百時美施貴寶的淨資產回報率為 8.83%，淨利潤率為-13.50%。該公司本季度的營收為 118.7 億美元，高於 114.5 億美元的共識預估。與去年同期相比，該季度公司的營收增長了 4.7%。</p>
</div><h2>Institutional Investors Weigh In On Bristol-Myers Squibb</h2>
<div class="lb-trans"><h2>機構投資者對百時美施貴寶的看法</h2>
</div><p>Hedge funds have recently made changes to their positions in the company. Northwest Financial Advisors purchased a new position in shares of Bristol-Myers Squibb in the fourth quarter valued at $27,000. ESL Trust Services LLC purchased a new position in shares of Bristol-Myers Squibb in the 1st quarter worth approximately $27,000. Accordant Advisory Group Inc bought a new position in shares of Bristol-Myers Squibb during the 1st quarter valued at approximately $31,000. Pacific Capital Wealth Advisors Inc. bought a new stake in Bristol-Myers Squibb in the fourth quarter worth about $34,000. Finally, Turtle Creek Wealth Advisors LLC purchased a new position in Bristol-Myers Squibb during the 4th quarter valued at $40,000. 76.41% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>對該公司的持股情況最近發生了變化。Northwest Financial Advisors 在第四季度購入了百時美施貴寶股票，價值 27000 美元。ESL Trust Services LLC 在第一季度購入了百時美施貴寶股票，價值約 27000 美元。Accordant Advisory Group Inc 在第一季度購入了百時美施貴寶股票，價值約 31000 美元。Pacific Capital Wealth Advisors Inc.在第四季度購入了百時美施貴寶股票，價值約 34000 美元。最後，Turtle Creek Wealth Advisors LLC 在第四季度購入了百時美施貴寶股票，價值 40000 美元。目前，76.41% 的股份由對沖基金和其他機構投資者持有。</p>
</div><h2>Bristol-Myers Squibb Announces Dividend</h2>
<div class="lb-trans"><h2>百時美施貴寶宣佈股息</h2>
</div><p>The firm also recently declared a quarterly dividend, which will be paid on Thursday, August 1st. Shareholders of record on Friday, July 5th will be paid a $0.60 dividend. The ex-dividend date of this dividend is Friday, July 5th. This represents a $2.40 annualized dividend and a yield of 5.78%. Bristol-Myers Squibb's payout ratio is -77.42%.</p>
<div class="lb-trans"><p>該公司最近宣佈了季度股息，將於 8 月 1 日星期四支付。股東記錄日期為 7 月 5 日星期五，將支付 0.60 美元的股息。該股息的除息日期為 7 月 5 日星期五。這代表了每年 2.40 美元的股息和 5.78% 的收益率。百時美施貴寶的派息比率為-77.42%。</p>
</div><h2>Bristol-Myers Squibb Company Profile (Get Free Report)</h2>
<div class="lb-trans"><h2>百時美施貴寶公司簡介（獲取免費報告）</h2>
</div><p>Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.</p>
<div class="lb-trans"><p>百時美施貴寶公司在全球範圍內發現、開發、許可、製造、市場、分銷和銷售生物製藥產品。它提供用於血液病學、腫瘤學、心血管病學、免疫學、纖維化和神經科學疾病的產品。該公司的產品包括 Eliquis，用於降低非瓣膜性心房顫動患者的中風/全身栓塞風險，並用於 DVT/PE 的治療；Opdivo，用於各種抗癌適應症，包括膀胱癌、血液癌、CRC、頭頸癌、RCC、HCC、肺癌、黑色素瘤、MPM、胃癌和食道癌；Pomalyst/Imnovid，用於多發性骨髓瘤；Orencia，用於活動性類風濕關節炎和銀屑病性關節炎；以及 Sprycel，用於費城染色體陽性慢性髓細胞白血病的治療。</p>
</div><h2>Featured Articles</h2>
<ul>
<li>Five stocks we like better than Bristol-Myers Squibb</li>
<li>Market Cap Calculator: How to Calculate Market Cap</li>
<li>Upwork Stock’s Outlook: Numbers Solid Despite Gen-AI Challenges</li>
<li>Using the MarketBeat Dividend Yield Calculator</li>
<li>What's Behind Walgreens Stock Plunge: What Investors Can Do Next</li>
<li>Procter &amp; Gamble NYSE: PG Pulls Back After Shaky Guidance</li>
<li>MarketBeat Week in Review – 6/24 - 6/28</li>
</ul>
<div class="lb-trans"><h2>特色文章</h2>
<ul>
<li>我們喜歡的五支股票，比百時美施貴寶更好</li>
<li>市值計算器：如何計算市值</li>
<li>Upwork 股票前景：儘管面臨 Gen-AI 挑戰，數字仍穩固</li>
<li>使用 MarketBeat 股息率計算器</li>
<li>瓦爾格林股票暴跌背後：投資者下一步該怎麼做</li>
<li>寶潔 NYSE: PG 在搖擺的指引後回落</li>
<li>MarketBeat 周評 - 6/24 - 6/28</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NYSE&amp;Symbol=BMY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>這則即時新聞警報是由敍事科技和來自 MarketBeat 的金融數據生成，旨在為讀者提供最快速和最準確的報道。在發佈之前，該故事已經經過 MarketBeat 編輯團隊的審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><p>→ Trump’s arrest is phase one (From Porter &amp; Company)(Ad)</p>
<div class="lb-trans"><p>→ 特朗普的逮捕是第一階段（來自 Porter &amp; Company）(廣告)</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NjAw" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=8600&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Bristol-Myers Squibb right now?</h2>
<div class="lb-trans"><h2>現在是否值得投資$1,000 美元購買百時美施貴寶？</h2>
</div><p>Before you consider Bristol-Myers Squibb, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮購買百時美施貴寶之前，您可能想聽聽這個消息。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bristol-Myers Squibb wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街評級最高、表現最佳的研究分析師以及他們推薦給客户的股票。MarketBeat 已經確定了五隻頂級分析師悄悄告訴他們的客户現在應該購買的股票...而百時美施貴寶並不在名單上。</p>
</div><p>While Bristol-Myers Squibb currently has a &#34;Hold&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然百時美施貴寶目前在分析師中被評為 “持有” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

分析師上調了百時美施貴寶（NYSE:BMY）2024 年第四季度的每股收益預期